ClinicalTrials.gg
Active, not recruitingNCT05059262MOTIONUpdated Mar 20, 2026Results posted

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

A Phase 3 interventional study of Vimseltinib and Placebo in Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis and Giant Cell Tumor of Tendon Sheath, sponsored by Deciphera Pharmaceuticals, LLC. Active, not recruiting at 35 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Primary conditionSynovitis, Pigmented VillonodularRegistry: Giant Cell Tumor of Tendon SheathReclassifiedWhy we changed it
Registry
Giant Cell Tumor of Tendon Sheath — the first condition term the registry derived for this study.
ClinicalTrials.gg
Synovitis, Pigmented Villonodular
Why
  1. The study's listed conditions name Synovitis, Pigmented Villonodular, a narrower term within Giant Cell Tumor of Tendon Sheath.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Deciphera Pharmaceuticals, LLC (part of Ono Pharmaceutical Co. Ltd) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Synovitis, Pigmented Villonodular with a site in United States — none open to participants now, 4 under way, 3 of them phase 3. Synovitis, Pigmented Villonodular · United States.

Enrollment
2nd of 12
123 · median 51
Started
2021
with 1 other
Phase 3
4 of 13
none open now
Registered
10th of 13
by date
Lead sponsor
2 of 13
Deciphera Pharmaceuticals, LLC

Among the 13 studies in Synovitis, Pigmented Villonodular with a site in United States, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2021, is one of 4 in phase 3, and was the 10th registered.

Synovitis, Pigmented Villonodular

20 studies on the registry are indexed under Synovitis, Pigmented Villonodular; 2 are open to participants now.

Browse Synovitis, Pigmented Villonodular studies →

Open to participants now

None of the 13 studies in Synovitis, Pigmented Villonodular with a site in United States is open now. The open studies under Synovitis, Pigmented Villonodular, anywhere →

Who these studies take

Of the 1 Synovitis, Pigmented Villonodular study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Synovitis, Pigmented Villonodular with a site in United States as a file.
02

Study summary

This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option.

The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either vimseltinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Participants assigned to placebo in Part 1 will have the option to receive vimseltinib for Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label vimseltinib.

03

Conditions studied

  • Tenosynovial Giant Cell Tumor
  • Pigmented Villonodular Synovitis
  • Giant Cell Tumor of Tendon Sheath
  • Tenosynovial Giant Cell Tumor, Diffuse
  • Tenosynovial Giant Cell Tumor, Localized

Browse trials for

Keywords

  • TGCT
  • PVNS
04

In context

Synovitis, Pigmented Villonodular Reclassified

20 studies on the registry are indexed under Synovitis, Pigmented Villonodular; 2 are open to participants now.

This study's enrollment of 123 is above the median of 36 across 17 interventional studies indexed under Synovitis, Pigmented Villonodular.

Browse Synovitis, Pigmented Villonodular studies →

Lead sponsor

Deciphera Pharmaceuticals, LLC is the lead sponsor of 24 studies on the registry; 5 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

First submitted before Deciphera Pharmaceuticals, LLC became part of Ono Pharmaceutical Co. Ltd.

Compared within Synovitis, Pigmented Villonodular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Giant Cell Tumor of Tendon Sheath. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥18 years of age
  2. TGCT for which surgical resection is not an option (tumor to confirm diagnosis required if no histology/pathology available at screening)
  3. Symptomatic disease as defined as at least moderate pain or at least moderate stiffness (defined as a score of 4 or more, with 10 describing the worst condition) within the screening period and documented in the medical record
  4. Participants should complete 14 consecutive days of questionnaires during the screening period and must meet minimum requirements as outlined in study protocol
  5. Must have stable analgesic regimen, as judged by the investigator, for at least 2 weeks prior to first dose of study drug
  6. Must have , as per Version 1.1, with at least one lesion having a minimum size of 2cm
  7. Adequate organ and bone marrow function
  8. If a female of , must have a negative pregnancy test prior to enrollment and agree to follow the requirements
  9. Must provide signed consent to participate in the study and is willing to comply with study-specific procedures
  10. Willing and able to complete the patient-reported outcome (PRO) assessments on an electronic device

Exclusion criteria

Exclusion Criteria:

  1. Previous use of systemic therapy ( or approved) targeting colony-stimulating factor 1 (CSF1) or colony-stimulating factor 1 receptor (CSF1R); previous therapy with imatinib and nilotinib is allowed
  2. Received therapy for TGCT, including investigational therapy during the screening period. Participated in a non-TGCT investigational drug study within 30 days of screening.
  3. Known TGCT or other active cancer that requires concurrent treatment (exceptions will be considered on a case-by-case basis)
  4. corrected by Fridericia's formula (QTcF) >450 ms in males or >470 ms in females or history of long QT syndrome
  5. Concurrent treatment with any study-prohibited medications
  6. Major surgery within 14 days of the first dose of study drug
  7. Any comorbidities
  8. Active liver or biliary disease including nonalcoholic steatohepatitis (NASH) or cirrhosis
  9. Malabsorption syndrome or other illness that could affect oral absorption
  10. Known active (HIV), acute or chronic , acute or chronic , or known active mycobacterium tuberculosis infection
  11. If female, the participant is pregnant or breastfeeding
  12. Known allergy or to any component of the study drug
  13. to MRI
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Part 1/Part 2 - Vimseltinib/Vimseltinib

    Participants received blinded treatment of 30 mg twice a week (BIW) vimseltinib for 24 weeks in Part 1 and open-label 30 mg BIW vimseltinib in Part 2.

    Drug: Vimseltinib

  • Placebo comparator
    Part 1/Part 2: Placebo/Vimseltinib

    Participants received blinded treatment of BIW matching placebo for 24 weeks in Part 1 and open-label 30 mg BIW vimseltinib in Part 2.

    Drug: Vimseltinib · Drug: Placebo

Interventions

  • Administered orally

    Also known as: DCC-3014

  • DrugPlacebo

    Administered orally

07

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) at Week 25 Per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1

    ORR was assessed by blinded independent radiologic review (IRR) using RECIST Version 1.1. ORR was defined as the percentage of participants who achieved either complete response (CR) or partial response (PR). * CR: Disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeter (mm) in short axis. Non-nodal targets must be absent. * PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Baseline to Week 25 (Cycle 7, Day 1)

Secondary outcomes

  1. ORR at Week 25 Per Tumor Volume Score (TVS)

    TVS is a semi-quantitative magnetic resonance imaging (MRI) scoring system that describes tumor mass and is based on 10% increments of the estimated volume of the maximally distended synovial cavity or tendon sheath involved. A tumor that is equal in volume to that of a maximally distended synovial cavity or tendon sheath was scored 10; a score of 0 indicated no evidence of tumor. ORR was the percentage of participants who achieved either CR or PR as assessed by blinded IRR using TVS. * CR: Lesion completely gone * PR: ≥50% decrease in volume score relative to Baseline.

    Time frame: Baseline to Week 25 (Cycle 7, Day 1)

  2. Change From Baseline in Active Range of Motion (ROM) at Week 25

    Presented here is the change from baseline in active ROM to Week 25. Measurement of the affected and contralateral, non-affected joint was assessed by goniometer and measured in degrees. At baseline, the motion with the smallest relative ROM value (worst) was identified, and this motion was used for evaluating the change in relative ROM subsequently. The affected joint measurement was used to derive a relative ROM based on active measurement relative to reference standard value provided by the American Medical Association. Relative ROM is expressed in percent: 100 x (joint ROM measure)/(reference ROM standard).

    Time frame: Baseline to Week 25 (Cycle 7, Day 1)

  3. Change From Baseline in the Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 25

    All participants were asked 15 questions from the PROMIS-PF item bank. The questions used one of two 5-point verbal rating scales: either 1 = "unable to do", 2 = "with much difficulty", 3 = "with some difficulty", 4 = "with a little difficulty", and 5 = "without any difficulty"; or 1 = "cannot do", 2 = "quite a lot", 3 = "somewhat", 4 = "very little", and 5 = "not at all." Total scores were converted to T-scores that ranged from 0 to 100, with higher scores representing less physical function interference and better health outcomes.

    Time frame: Baseline to Week 25 (Cycle 7, Day 1)

  4. Change From Baseline in the Worst Stiffness Numeric Rating Scale (NRS) Score at Week 25

    The Worst Stiffness NRS is a single question that asks the participant to assess their worst stiffness in the last 24 hours. Participants rate their worst stiffness on a scale of 0 to 10, where 0 is "no stiffness" and 10 is "worst imaginable." Lower scores represented better level of stiffness.

    Time frame: Baseline to Week 25 (Cycle 7, Day 1)

  5. Change From Baseline in EuroQoL Visual Analogue Scale (EQ-VAS) at Week 25

    The EQ-VAS is a standardized tool for measuring overall health. EQ-VAS recorded the participant's self-rated health on a vertical VAS scale ranging from a minimum of 0 (worst imaginable health state) to a maximum of 100 (best imaginable health state). Higher scores indicated better health state.

    Time frame: Baseline to Week 25 (Cycle 7, Day 1)

  6. Percentage of Participants With Response at Week 25 Based on Brief Pain Inventory (BPI) Worst Pain NRS Score and Narcotic Analgesic Use

    Participants reported responses to the BPI Worst Pain NRS. The BPI Worst Pain NRS ranged from 0 to 10, where 0 is "no pain" and 10 is "pain as bad as you can imagine." A responder was defined as a participant who: (i) experienced a decrease of at least 30% in the mean BPI Worst Pain NRS item and (ii) did not experience a 30% or greater increase in narcotic analgesic use.

    Time frame: Baseline to Week 25 (Cycle 7, Day 1)

08

Results

Posted Feb 24, 2025

Participant flow

Part 1: Double Blind (Weeks 1 - 24)
Participant flow — Part 1: Double Blind (Weeks 1 - 24)
MilestonePart 1/Part 2: Vimseltinib/VimseltinibPart 1/Part 2: Placebo/Vimseltinib
Started8340
Received at least 1 dose of study drug8339
Completed7535
Not completed85
Withdrew: Subsequent tgct therapy and/or surgery30
Withdrew: Withdrawal by subject33
Withdrew: Physician decision11
Withdrew: Other reasons01
Withdrew: Ongoing in study10
Part 2: Open Label (Weeks 25 - EoS)
Participant flow — Part 2: Open Label (Weeks 25 - EoS)
MilestonePart 1/Part 2: Vimseltinib/VimseltinibPart 1/Part 2: Placebo/Vimseltinib
Started7435
Received at least 1 dose of study drug7235
Completed00
Not completed7435
Withdrew: Death10
Withdrew: Withdrawal by subject01
Withdrew: Lost to follow-up02
Withdrew: Ongoing in study7332

Outcome measures

PrimaryObjective Response Rate (ORR) at Week 25 Per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1

ORR was assessed by blinded independent radiologic review (IRR) using RECIST Version 1.1. ORR was defined as the percentage of participants who achieved either complete response (CR) or partial response (PR). * CR: Disappearance of all target lesions. Any pathological lymph nodes must be \<10 millimeter (mm) in short axis. Non-nodal targets must be absent. * PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Baseline to Week 25 (Cycle 7, Day 1)
Reported as:
Number · percentage of participants with CR or PR
Objective Response Rate (ORR) at Week 25 Per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1
percentage of participants with CR or PRVimseltinibPlacebo
Objective Response Rate (ORR) at Week 25 Per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.139.8 (29.2 to 51.1)0 (0.0 to 8.8)
Statistical analysis
  • Vimseltinib vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Stratified by tumor location (lower limb/all other) and region (U.S./non-U.S.) based on Interactive Response Technology (IRT).) · Difference in orr: 39.0 · 95% CI 28.4 to 49.6Stratified Mantel-Haenszel with stratification factors based on IRT
SecondaryORR at Week 25 Per Tumor Volume Score (TVS)

TVS is a semi-quantitative magnetic resonance imaging (MRI) scoring system that describes tumor mass and is based on 10% increments of the estimated volume of the maximally distended synovial cavity or tendon sheath involved. A tumor that is equal in volume to that of a maximally distended synovial cavity or tendon sheath was scored 10; a score of 0 indicated no evidence of tumor. ORR was the percentage of participants who achieved either CR or PR as assessed by blinded IRR using TVS. * CR: Lesion completely gone * PR: ≥50% decrease in volume score relative to Baseline.

Time frame:
Baseline to Week 25 (Cycle 7, Day 1)
Reported as:
Number · percentage of participants
ORR at Week 25 Per Tumor Volume Score (TVS)
percentage of participantsVimseltinibPlacebo
ORR at Week 25 Per Tumor Volume Score (TVS)67.5 (56.3 to 77.4)0 (0.0 to 8.8)
Statistical analysis
  • Vimseltinib vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Stratified by tumor location (lower limb/all other) and region (U.S./non-U.S.) based on IRT.) · Difference in orr: 67.2 · 95% CI 57.0 to 77.3Stratified Mantel-Haenszel with stratification factors based on IRT.
SecondaryChange From Baseline in Active Range of Motion (ROM) at Week 25

Presented here is the change from baseline in active ROM to Week 25. Measurement of the affected and contralateral, non-affected joint was assessed by goniometer and measured in degrees. At baseline, the motion with the smallest relative ROM value (worst) was identified, and this motion was used for evaluating the change in relative ROM subsequently. The affected joint measurement was used to derive a relative ROM based on active measurement relative to reference standard value provided by the American Medical Association. Relative ROM is expressed in percent: 100 x (joint ROM measure)/(reference ROM standard).

Time frame:
Baseline to Week 25 (Cycle 7, Day 1)
Reported as:
Least squares mean · Change in percent
Change From Baseline in Active Range of Motion (ROM) at Week 25
Change in percentVimseltinibPlacebo
Change From Baseline in Active Range of Motion (ROM) at Week 2518.4 ± 6.463.8 ± 7.19
Statistical analysis
  • Vimseltinib vs Placebo · Mixed model repeated measures · p = 0.0077 (Model included treatment+visit+treatment by visit interaction+stratification factor for region (U.S. versus non-U.S.)+joint type (knee, ankle, or other)+the most impaired ROM baseline value.) · Ls mean difference: 14.6 · 95% CI 4.0 to 25.3
SecondaryChange From Baseline in the Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 25

All participants were asked 15 questions from the PROMIS-PF item bank. The questions used one of two 5-point verbal rating scales: either 1 = "unable to do", 2 = "with much difficulty", 3 = "with some difficulty", 4 = "with a little difficulty", and 5 = "without any difficulty"; or 1 = "cannot do", 2 = "quite a lot", 3 = "somewhat", 4 = "very little", and 5 = "not at all." Total scores were converted to T-scores that ranged from 0 to 100, with higher scores representing less physical function interference and better health outcomes.

Time frame:
Baseline to Week 25 (Cycle 7, Day 1)
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 25
score on a scaleVimseltinibPlacebo
Change From Baseline in the Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 254.6 ± 0.961.3 ± 0.88
Statistical analysis
  • Vimseltinib vs Placebo · Mixed model repeated measures · p = 0.0007 (Model included treatment+visit+treatment by visit interaction+stratification factor for region (U.S. versus non-U.S.) and tumor location (lower limb/all other) based on IRT+PROMIS-PF baseline value.) · Ls mean difference: 3.3 · 95% CI 1.4 to 5.2
SecondaryChange From Baseline in the Worst Stiffness Numeric Rating Scale (NRS) Score at Week 25

The Worst Stiffness NRS is a single question that asks the participant to assess their worst stiffness in the last 24 hours. Participants rate their worst stiffness on a scale of 0 to 10, where 0 is "no stiffness" and 10 is "worst imaginable." Lower scores represented better level of stiffness.

Time frame:
Baseline to Week 25 (Cycle 7, Day 1)
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Worst Stiffness Numeric Rating Scale (NRS) Score at Week 25
score on a scaleVimseltinibPlacebo
Change From Baseline in the Worst Stiffness Numeric Rating Scale (NRS) Score at Week 25-2.1 ± 0.24-0.3 ± 0.28
Statistical analysis
  • Vimseltinib vs Placebo · Mixed model repeated measures · p = <0.0001 (Model included treatment+visit+treatment by visit interaction+stratification factor for region (U.S. versus non-U.S.) and tumor location (lower limb/all other) based on IRT+Worst Stiffness NRS baseline value.) · Ls mean difference: -1.8 · 95% CI -2.5 to -1.1
SecondaryChange From Baseline in EuroQoL Visual Analogue Scale (EQ-VAS) at Week 25

The EQ-VAS is a standardized tool for measuring overall health. EQ-VAS recorded the participant's self-rated health on a vertical VAS scale ranging from a minimum of 0 (worst imaginable health state) to a maximum of 100 (best imaginable health state). Higher scores indicated better health state.

Time frame:
Baseline to Week 25 (Cycle 7, Day 1)
Reported as:
Least squares mean · score on a scale
Change From Baseline in EuroQoL Visual Analogue Scale (EQ-VAS) at Week 25
score on a scaleVimseltinibPlacebo
Change From Baseline in EuroQoL Visual Analogue Scale (EQ-VAS) at Week 2513.5 ± 2.356.1 ± 2.85
Statistical analysis
  • Vimseltinib vs Placebo · Mixed model repeated measures · p = 0.0155 (Model included treatment+visit+treatment by visit interaction+stratification factor for region (U.S. versus non-U.S.) and tumor location (lower limb/all other) based on IRT+VAS baseline value.) · Ls mean difference: 7.4 · 95% CI 1.4 to 13.4
SecondaryPercentage of Participants With Response at Week 25 Based on Brief Pain Inventory (BPI) Worst Pain NRS Score and Narcotic Analgesic Use

Participants reported responses to the BPI Worst Pain NRS. The BPI Worst Pain NRS ranged from 0 to 10, where 0 is "no pain" and 10 is "pain as bad as you can imagine." A responder was defined as a participant who: (i) experienced a decrease of at least 30% in the mean BPI Worst Pain NRS item and (ii) did not experience a 30% or greater increase in narcotic analgesic use.

Time frame:
Baseline to Week 25 (Cycle 7, Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Response at Week 25 Based on Brief Pain Inventory (BPI) Worst Pain NRS Score and Narcotic Analgesic Use
percentage of participantsVimseltinibPlacebo
Percentage of Participants With Response at Week 25 Based on Brief Pain Inventory (BPI) Worst Pain NRS Score and Narcotic Analgesic Use48.2 (37.1 to 59.4)22.5 (10.8 to 38.5)
Statistical analysis
  • Vimseltinib vs Placebo · Cochran-Mantel-Haenszel · p = 0.0056 (Stratified by tumor location (lower limb/all other) and region (U.S./non-U.S.) based on IRT.) · Difference in responder rate: 26.2 · 95% CI 9.5 to 42.8Stratified Mantel-Haenszel with stratification factors based on IRT.

Adverse events

Collected over Collection of adverse events started from the signing of informed consent through safety follow-up (up to 1.68 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Total - Vimseltinib1/118 (0.8%)17/118 (14.4%)113/118 (95.8%)
Placebo0/39 (0%)1/39 (2.6%)32/39 (82.1%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventTotal - VimseltinibPlacebo
CellulitisInfections and infestations4/1180/39
DiarrhoeaGastrointestinal disorders0/1181/39
VomitingGastrointestinal disorders0/1181/39
FallInjury, poisoning and procedural complications2/1180/39
Myocardial ischaemiaCardiac disorders1/1180/39
UveitisEye disorders1/1180/39
Inguinal herniaGastrointestinal disorders1/1180/39
Localised infectionInfections and infestations1/1180/39
ParonychiaInfections and infestations1/1180/39
Rhinovirus infectionInfections and infestations1/1180/39
Most frequent other events
Showing 10 of 42
Most frequent other events
EventTotal - VimseltinibPlacebo
Periorbital oedemaEye disorders53/1185/39
Face oedemaGeneral disorders34/1183/39
PruritusSkin and subcutaneous tissue disorders33/1183/39
FatigueGeneral disorders31/1186/39
HeadacheNervous system disorders30/11810/39
AstheniaGeneral disorders30/1189/39
Aspartate aminotransferase increasedInvestigations30/1181/39
NauseaGastrointestinal disorders26/1188/39
Blood creatine phosphokinase increasedInvestigations26/1180/39
RashSkin and subcutaneous tissue disorders25/1182/39

Baseline characteristics

The Intent-to-Treat (ITT) Set consisted of participants who were randomized to a study treatment regimen. Presented here are data from Part 1 baseline period.

Age, Continuous
Age, Continuous(years)Part 1/Part 2: Vimseltinib/VimseltinibPart 1/Part 2: Placebo/VimseltinibTotal
Mean43.8 ± 13.9242.5 ± 13.6743.4 ± 13.80
Sex: Female, Male
Sex: Female, Male(Participants)Part 1/Part 2: Vimseltinib/VimseltinibPart 1/Part 2: Placebo/VimseltinibTotal
Female462773
Male371350
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1/Part 2: Vimseltinib/VimseltinibPart 1/Part 2: Placebo/VimseltinibTotal
Hispanic or Latino314
Not Hispanic or Latino622385
Unknown or Not Reported181634
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1/Part 2: Vimseltinib/VimseltinibPart 1/Part 2: Placebo/VimseltinibTotal
American Indian or Alaska Native000
Asian145
Native Hawaiian or Other Pacific Islander000
Black or African American404
White592180
More than one race000
Unknown or Not Reported191534
09

Study locations

35 sites
10

References and documents

Publications

  • Gelderblom H, Bhadri V, Stacchiotti S, Bauer S, Wagner AJ, van de Sande M, Bernthal NM, Lopez Pousa A, Razak AA, Italiano A, Ahmed M, Le Cesne A, Tinoco G, Boye K, Martin-Broto J, Palmerini E, Tafuto S, Pratap S, Powers BC, Reichardt P, Casado Herraez A, Rutkowski P, Tait C, Zarins F, Harrow B, Sharma MG, Ruiz-Soto R, Sherman ML, Blay JY, Tap WD; MOTION investigators. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 Jun 22;403(10445):2709-2719. doi: 10.1016/S0140-6736(24)00885-7. Epub 2024 Jun 3. PubMed 38843860 ↗
  • Tap WD, Sharma MG, Vallee M, Smith BD, Sherman ML, Ruiz-Soto R, de Sande MV, Randall RL, Bernthal NM, Gelderblom H. The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor. Future Oncol. 2024 Mar;20(10):593-601. doi: 10.2217/fon-2023-0238. Epub 2023 Aug 18. PubMed 37593881 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Aug 2023, 21 months.

Results were first posted in Feb 2025, 1 year 6 months after primary completion. A results delay was requested in Aug 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2021
First posted
Sep 28, 2021
StartActual
Oct 14, 2021
Primary completionActual
Aug 10, 2023
CompletionEst.
Jul 2028
Results delay requested
Aug 8, 2024
Results first posted
Feb 24, 2025
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05059262
Responsible party
Sponsor
First posted
Sep 28, 2021
Start date
Oct 14, 2021
Primary completion
Aug 10, 2023
Completion
Jul 2028 (estimated)
Results posted
Feb 24, 2025
Last update
Mar 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vimseltinib

Start the discussion